Merck said the pivotal phase III KEYNOTE-042 trial evaluating Keytruda, Merck’s anti-PD-1 therapy, as monotherapy for the first-line treatment of locally advanced or metastatic non-small cell lung cancer (including nonsquamous or squamous histologies) met its primary endpoint of overall survival.
Do multi-cancer detection tests provide a net benefit? NCI aims to answer this question, beginning with the Vanguard feasibility trial which recently started accruing patients.
